Nu Skin Still Has Long-Term Turnaround Potential

Nu Skin is rated a buy, trading at low multiples with turnaround prospects tied to India expansion and Prysm iO device launch. NUS's core MLM business faces structural decline, but new product and market initiatives could stabilize or grow revenue beyond 2026. Prysm iO potential subscription fees may provide incremental revenue not fully reflected in current guidance.

Seeking Alpha • Feb 19, 2026

Nu Skin Enterprises Q4 Earnings Lag Estimates, Revenues Down Y/Y

NUS' fourth-quarter earnings and sales miss estimates, with revenues down 16.9% Y/Y and broad declines across key global regions.

Zacks Investment Research • Feb 13, 2026

Stonegate Capital Partners Updates Coverage on NU Skin Enterprises Inc. (NUS) 2025 Q4

Dallas, Texas--(Newsfile Corp. - February 13, 2026) - NU Skin Enterprises Inc. (NYSE: NUS): Stonegate Capital Partners updates their coverage on NU Skin Enterprises Inc. (NYSE: NUS). NUS reported revenue, adj NI, and adj EPS of $370.3M, $14.5M, and $0.29, respectively.

Newsfile Corp • Feb 13, 2026

Top 3 Defensive Stocks That May Rocket Higher In February

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.

Benzinga • Feb 13, 2026

Nu Skin Enterprises, Inc. (NUS) Q4 2025 Earnings Call Transcript

Nu Skin Enterprises, Inc. (NUS) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 13, 2026

Nu Skin Enterprises Announces Quarterly Dividend

PROVO, Utah--(BUSINESS WIRE)--Nu Skin Enterprises, Inc. (NYSE: NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on Mar. 11, 2026, to shareholders of record on Feb. 27, 2026. About Nu Skin Enterprises Inc. Nu Skin Enterprises Inc. (NYSE: NUS) is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scien.

Business Wire • Feb 12, 2026

Nu Skin Enterprises Reports Fourth Quarter and Full-year 2025 Results Within Guidance

PROVO, Utah--(BUSINESS WIRE)--Nu Skin Enterprises Inc. (NYSE: NUS) today announced fourth quarter and full-year 2025 revenue and earnings within guidance with more than 50% growth in earnings for 2025. Executive Summary Q4 2025 vs. Prior-year Quarter Revenue $370.3 million; (16.9)% or (10.4)% excluding Mavely 2024 revenue (0.2)% FX impact or $(0.8) million Earnings Per Share (EPS) $0.29 compared to $(0.73) or $0.38 excluding restructuring and other charges Customers 748,796; (10)% Paid Affiliat.

Business Wire • Feb 12, 2026

Nu Skin Enterprises (NUS) Q4 Earnings and Revenues Miss Estimates

Nu Skin Enterprises (NUS) came out with quarterly earnings of $0.29 per share, missing the Zacks Consensus Estimate of $0.3 per share. This compares to earnings of $0.38 per share a year ago.

Zacks Investment Research • Feb 12, 2026

Nu Skin Gears Up to Report Q4 Earnings: What's in the Offing?

NUS faces FX and competition headwinds as it guides Q4 revenues down 10-18%, while margin gains and Latin America strength offer support.

Zacks Investment Research • Feb 11, 2026

Dr. Joseph Chang Launches Update to Bestselling Book "The Aging Myth" With 15 More Years of Breakthrough Research on Cellular Wellness

PROVO, Utah--(BUSINESS WIRE)--Nu Skin Enterprises Inc. (NYSE: NUS) today announced the relaunch of “The Aging Myth: Unlocking the Mysteries of Looking and Feeling Young,” the updated edition of the bestselling book from Dr. Joseph Chang, chair of Nu Skin's Scientific Advisory Board. The relaunch marks a significant milestone in the evolution of evidence-based beauty and wellness, bringing together decades of research that underpin Nu Skin's science-led innovations — from ageLOC® technology to t.

Business Wire • Feb 6, 2026